Table 2

Clinical benefits from adding cetuximab to a PD-1 inhibitor therapy according to p16 status

ComparisonORR1-year OS rate *
Rate (%)OR (95% CI)P effectP homogeneityRate (%)Ratio of rate (95% CI)P effect
Cetuximab plus anti-PD-1 versus anti-PD-1 in p16-positive patients18 versus 171.19 (0.51 to 2.74)0.6860.69555 versus 401.37 (0.80 to 2.36)0.252
Cetuximab plus anti-PD-1 versus anti-PD-1 in p16-negative patients46 versus 155.45 (2.79 to 10.64)<0.0010.38959 versus 361.62 (1.26 to 2.07)<0.001
p16-positive versus p16-negative patients after cetuximab plus anti-PD-1 therapy18 versus 460.29 (0.13 to 0.68)0.0040.81855 versus 590.95 (0.55 to 1.62)0.850
  • *Due to the lack of data, tests for heterogeneity could not be conducted.

  • OR, odds ratio; ORR, Objective response rate; OS, overall survival; PD-1, programmed cell death protein 1.